Strategic Outsourcing and Global Drug Development –
March 2008; Vol. 3 No. 2

The trend to outsource key elements of drug development to service providers could slow down in the future, due in part to rising operating costs worldwide.

As sponsors seek higher levels of development performance and efficiency, they are poised to move from transactional outsourcing to more strategic partnerships. This report summarizes a recently convened executive roundtable on the issue.